New ETF Book by Larry Connors - Click here to read more
Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420.
-------------------------------------------
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) closed at $0.115 Friday, trading 450,375 shares.
Company News- August 25, 2008: Infinity Medical Group Inc. Receives Building Permit for 18 Yonge Street Projects
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) is pleased to have announced earlier today that it has received the Building permit for its 18 Yonge Street project which will be home to a Rejuvena Med Spa and a Dental Implant Clinic. The 18 Yonge Street project is a commercial retail space at the bottom of a 39 storey Condominium complex an easy walk to the Waterfront, Air Canada Centre, Union Station, Financial District and the 48 storey 872 unit Maple Leaf Square Condominium. New-condominium sales in the City of Toronto were up 45.7 per cent last year, going from 13,535 units in 2006 to 19,724 in 2007 according to officials from the Building Industry and Land Development Association (BILD), announced on 2/22/2008 in a news release. Downtown Toronto is undergoing a building boom. According to an unofficial estimate assembled by National Post staff on December 19th 2007, the vertical expansion totals about 3,005 storeys, including at least 37,355 condo units. This phenomenon in Toronto's Downtown core has created an exceptional opportunity for Infinity Medical to offer its Cosmetic Medical Laser and Dental Implant services to this underserviced area of Toronto.
Receiving this permit is the next step for Infinity Medical Group in building a presence in the downtown condominium market who's demographic is exactly the same aging Baby Boomer demographic that both Rejuvena and our Dental Implant Clinics seek as clients.
About Infinity Medical Group Inc.:
Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics offering elective procedures.
About Dental Implants Dental implants are designed as permanent replacements for missing teeth. A dental implant is a metal post that is surgically placed into the bone under the gums. The purpose of the placement into the bone is to encourage the integration of the dental implants. The bone actually grows around the dental implant, making the tooth secure. A replacement tooth is attached to the titanium post by means of a final abutment.
About Medical Spas
Medical spa is a hybrid between a medical clinic and a day spa that operates under the supervision of medical doctor. Medical Spa Treatments include laser treatments (Lasers are medical devices used to treat a variety of conditions, including unwanted hair, uneven pigmentation, wrinkles, and broken capillaries. The word laser is an acronym for "light amplification by stimulated emission of radiation." Lasers use a direct beam of radiation that penetrates the deeper level of the skin, called the dermis, and creates a reaction), IPL (intense pulsed light) treatment, microdermabrasion, photofacials, injectables like Botox and fillers, peels and skin tightening.
-------------------------------------------
Remedent, Inc. (OTCBB: REMI | Quote | Chart | News | PowerRating) closed at $1.45 Friday, trading 12,550 shares.
Company News- August 25, 2008: Remedent, Inc. and Den-Mat Holdings, LLC Sign Collaboration and International Distribution Agreement
Two leaders in cosmetic dentistry, Remedent, Inc. (OTCBB: REMI | Quote | Chart | News | PowerRating) and Den-Mat Holdings, LLC, announced earlier today that Den-Mat has obtained the exclusive rights to manufacture, market and distribute Remedent's innovative GlamSmile products and technologies in North America and numerous international markets.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About Remedent
Remedent, Inc. develops, manufactures and markets oral care and cosmetic dentistry products with distribution in more than 35 countries. Based in Deurle, Belgium and El Segundo, CA, Remedent serves both the professional dental community and the consumer over-the-counter market. Visit www.remedent.com for further information.
GlamSmile is a revolutionary cosmetic dental system that substantially expands the consumer and professional dental market for veneers. To produce the veneers, Remedent utilizes high-tech scanning, CAD/CAM design technology, and a proprietary fabrication technique. The veneers are delivered to a dentist already prepared for a simple, single-motion veneer placement. This patent-pending painless delivery system not only dramatically lowers the dentist's cost of installation, but also significantly reduces the amount of time patients spend in the dental chair. The result is unprecedented pricing for veneers which previously were only within the reach of affluent patients.
About Den-Mat Holdings, LLC
California-based Den-Mat Holdings, LLC is a leading manufacturer and marketer of advanced cosmetic and restorative dental products and laboratory services that allow a dentist to preserve, restore and enhance their patient's teeth typically without the requirement for anesthesia, extensive cutting, drilling and tooth removal. This revolutionary type of dentistry not only focuses on superior esthetic results, but on patient comfort and convenience as well.
Den-Mat's revolutionary LUMINEERS BY CERINATE are porcelain veneers that offer a painless way to a permanently whiter and perfectly aligned smile. LUMINEERS are the only porcelain laminates that are strong, reversible, and have a proven record of over 20 years of clinical success. The dentist applies these contact lens-thin veneers to teeth without the need for the shaving and grinding down of sensitive tooth structure that is common with traditional veneers.
Den-Mat currently has approximately 700 employees and manufactures a complete line of more than 200 cosmetic and restorative formulations. The company services approximately 40,000 dentists worldwide, and offers variety of educational seminars and marketing support services for dentists. For additional information, please visit www.denmat.com.
About Credit Suisse
As one of the world's leading banks, Credit Suisse provides its clients with investment banking, private banking and asset management services worldwide. Credit Suisse offers advisory services, comprehensive solutions and innovative products to companies, institutional clients and high-net worth private clients globally, as well as retail clients in Switzerland. Credit Suisse is active in over 50 countries and employs approximately 40,000 people. Credit Suisse's parent company, Credit Suisse Group, is a leading global financial services company headquartered in Zurich. Credit Suisse Group's registered shares (CSGN) are listed in Switzerland and, in the form of American Depositary Shares (CS), in New York. Further information about Credit Suisse can be found at www.creditsuisse.com.
-------------------------------------------
Longs Drug Stores Corporation (NYSE: LDG) closed at $72.10 Friday, trading 1,207,900 shares.
Company News- August 20, 2008: Longs Drug Stores Corporation Reports Second Quarter Results
Longs Drug Stores Corporation (NYSE: LDG) yesterday reported preliminary income from continuing operations for the second quarter ended July 31, 2008 of $27.5 million, or $0.76 per diluted share, including $0.7 million of after-tax charges, or $0.02 per diluted share, related to provisions for store closures and asset impairments and legal reserves, a 6.8 percent increase compared with income from continuing operations for the second quarter ended July 26, 2007 of $25.7 million, or $0.67 per diluted share.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About the Long Drugs Corpaoration
Headquartered in Walnut Creek, California, Longs Drug Stores Corporation (NYSE: LDG) is one of the most recognized retail drug store chains on the West Coast and in Hawaii. The Company operates 521 retail pharmacies and offers a wide assortment of merchandise focusing on health, wellness, beauty and convenience. Longs also provides pharmacy benefit management services and Medicare beneficiary prescription drug plans through its wholly-owned subsidiary, RxAmerica, LLC. Additional information about Longs and its services is available at http://www.longs.com and more information about RxAmerica is available at http://www.rxamerica.com.
-------------------------------------------
Chemtura Corporation (NYSE: CEM) closed at $6.36 Friday, trading 3,137,900 shares.
Company News- August 20, 2008: Chemtura and Venomix Extend Collaboration
Chemtura Corporation (NYSE: CEM) and Venomix, Inc. have agreed to extend their collaboration on the development of insecticides based on spider venom peptides, the companies announced yesterday. The companies began their collaboration in 2006. Since then, Chemtura has made payments to Venomix for the achievement of scientific milestones. During the extended collaboration, the companies will agree annually on research milestones and payments. The financial terms of the original agreement and the extension have not been disclosed.
The collaboration centers on the discovery that peptides contained in spider venom have insecticidal properties. Venomix has isolated and characterized a number of these peptides, which are lethal to insects but harmless to non-target species, including humans. One of these peptides, designated "hybrid," is the object of the collaboration.
The first goal of the collaboration is to develop the "hybrid" peptide as a commercial insecticide. Longer term, the companies will collaborate to produce small, chemical molecules that "fit" the same receptor as the "hybrid" peptide. This is expected to lead to chemical pesticides with the same biological activity and safety profile as the "hybrid" peptide.
John L. McIntyre, Ph.D., President and CEO of Venomix, said, "The collaboration with Chemtura has gone extremely well. We have an excellent relationship and we both see greater opportunity now from the collaboration than we did when we started."
Gregory E. McDaniel, Group President for Crop Protection, Chemtura said, "We are very excited about the hybrid peptide technology and our ongoing collaboration with Venomix. This technology has been shown to provide control against a number of commercially important crop insects and has the potential to significantly enhance our current portfolio."
About Chemtura
Chemtura Corporation, with 2007 sales of $3.7 billion, is a global manufacturer and marketer of polymer additives, performance specialties, consumer products and crop protection products. Additional information concerning Chemtura is available at http://www.chemtura.com.
Venomix is developing a new generation of insecticides using peptides from spiders. The company's technology is based on ground-breaking research conducted at the University of Connecticut. Over 50 unique, spider-venom peptides have been identified. This patented technology is exclusively licensed to Venomix. Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. Venomix products will be ideally suited for the environmentally conscious twenty-first century. http://www.Venomix.net
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.associatesfortune.com, www.businessnetwire.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com, financialbusinessnews.us and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage
CONTACT: Stock Profiler.US Tel: +1 603 424 4420 e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
